Arvid Carlsson Award by Sahlgrenska Science Park 2018 was awarded to the founders of 1928 Diagnostics, Kristina Lagerstedt and Susanne Staaf with the following motivation:
The winners of Arvid Carlsson Award by Sahlgrenska Science Park 2018 are internationally recognized through a technique that is considered to be pioneer in solving one of the world’s largest threats to human health. Antibiotic resistance.
With a global mindset from start in 2014, the Gothenburg-based company is already active in more than ten countries throughout Europe and is now planning future expansion in the US.
The founders show that dedication and true entrepreneurial spirit for a good cause based on research can make a difference in the world.
Starting in 2017, Sahlgrenska Science Park awards the Arvid Carlsson Award every year in September. The aim is to pay tribute to innovation, knowledge and competence in conjunction with good entrepreneurship through an award in Nobel Prize winner Arvid Carlsson’s name.
It is in line with Sahlgrenska Science Park’s vision of a world-class life science region, and is awarded to an entrepreneur who drives development forward for human health and wellbeing.
The ambition is to give recognition and honor to promising and future entrepreneurs in academia, healthcare and industry to stimulate continued learning and networking in the global arena that is life science. Arvid Carlsson, who was awarded the Nobel Prize in medicine in 2000 for his ” ”for discoveries concerning signal transduction in the nervous system”, is still active in his company, A. Carlsson Research, at Sahlgrenska Science Park in Gothenburg today.
Arvid Carlsson is a true inspiration and entrepreneur in our environment, and his work has not only been crucial in research and medicine but he is still driven by curiosity and ambition to solve major health problems,” says Charlotta Gummeson, CEO of Sahlgrenska Science Park.
”I am very happy and proud to give name to an award that strengthens and praises innovation and entrepreneurship while emphasizing the importance of constant competence development,” says Arvid Carlsson.
Facts about the Arvid Carlsson Award by Sahlgrenska Science Park
Who can get the award?
Nominated entrepreneurs in life science who drive development for human health and wellbeing.
What does the prize consist of ?
In addition to honors and diplomas, the prize consists of a challenge prize as well as participation in an international conference including travel and accommodation.
Lessons learned from the conference will be described afterwards in conjunction with a lecture for entrepreneurs and companies at Sahlgrenska Science Park.
The jury consists of the Board of Sahlgrenska Science Park which represents the business community, University of Gothenburg, Sahlgrenska University Hospital, Chalmers University of Technology, Västra Götaland Region, Business Region Gothenburg and Mölndal City.
- Marianne Dicander Alexandersson, (Chairman)
- Ivan Mijakovic, Professor, Director of the Life Science Engineering Area of Advance Chalmers University of Technology
- Eva Wiberg, Vice-Chancellor and Principal, University of Gothenburg
- Cecilia Dalman Eek, Member of the City Council, City of Gothenburg
- Birgitta Losman, Member The Region Västra Götaland
- Håkan Ahlström, City Director, Mölndal City
- Ann-Marie Wennberg, Professor and CEO Sahlgrenska University Hospital
This year, the prize was awarded on September 27, 2018 in conjunction with Park Annual by Sahlgrenska Science Park, organized for the 13th consecutive year.
About Nobel Prize winner Arvid Carlsson
Arvid Carlsson, born 1923, was awarded the Nobel Prize in medicine for ”discoveries concerning signal transduction in the nervous system ” in 2000. Among other things, he studied the neurotransmitters dopamine and serotonin. He shared the award with the Americans Paul Greengard and Eric R. Kandel. Arvid Carlsson’s research led to the recognition that Parkinson’s disease is caused by dopamine deficiency in some parts of the brain and subsequently to the production of Levodopa, an effective drug against this disease. Read more about Arvid Carlsson and the Nobel Prize here.